Novel insights in the management of sickle cell disease in childhood

Table 1 Recent series of human leukocyte antigen-identical transplant for sickle cell disease in children

Ref.	Conditioning regimen	n	Age range in years	Deaths	Follow-up (yr)	Outcome
Krishnamurti et al[82]	BU, Flu, eATG, total lymphoid irradiation	7	6-18	None	2-8.5	All patients alive EFS 86%
McPherson et al[83]	BU, CY, ATG	25	3.3-17.4	1	0.1-10	OS and DFS 96% (median survivor follow-4.9 yr)
Lucarelli et al[84]	BU, CY, rATG ± Flu	40	2-17	3	1-10	5-yr OS and DFS 91%
Dedeken et al[85]	BU, CY, ± rATG, ± HU	50	1.7-15.3	2	0.4-21.3	8-yr EFS 85.6% and OS 94.1%
Bhatia et al[86]	BU, Flu, Alem	18	2.3-20.2	None	0.4-7.5	2-yr EFS and OS both 100%
Soni et al[87]	BU, CY, rATG	15	1.5-18	None	0.9-7.5	3-yr EFS and OS both 100%

ATG: Antithymocyte globulin; BU: Busulfan; CY: Cyclophosphamide; DFS: Disease free survival; eATG: Equine antithymocyte globulin; EFS: Event free survival; Flu: Fludarabine; HU: Hydroxyurea; OS: Overall survival; rATG: Rabbit antithymocyte globulin; Alem: Alemtuzumab.